Dianthus Therapeutics (DNTH) Retained Earnings (2017 - 2025)

Dianthus Therapeutics' Retained Earnings history runs 9 years deep, the most recent figure standing at -$336.7 million for Q4 2025.

• In Q4 2025, Retained Earnings fell 93.09% year-over-year to -$336.7 million; the TTM figure through Dec 2025 stood at -$336.7 million (down 93.09% YoY), while the FY2025 annual figure was -$336.7 million, down 93.09% from the prior year.
• Retained Earnings for Q4 2025 stood at -$336.7 million, down from -$272.3 million in the prior quarter.
• The five-year high for Retained Earnings was -$45.9 million in Q4 2022, with the low at -$434.5 million in Q2 2023.
• The 5-year median for Retained Earnings is -$253.7 million (2021), against an average of -$232.9 million.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings soared 85.91% in 2022, then tumbled 97.58% in 2025.
• Dianthus Therapeutics' Retained Earnings stood at -$325.6 million in 2021, then jumped by 85.91% to -$45.9 million in 2022, then slumped by 94.96% to -$89.4 million in 2023, then slumped by 95.02% to -$174.4 million in 2024, then slumped by 93.09% to -$336.7 million in 2025.
• Business Quant data shows DNTH's Retained Earnings at -$336.7 million in Q4 2025, -$272.3 million in Q3 2025, and -$235.5 million in Q2 2025.